Compare Fulford India with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs SANOFI INDIA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA SANOFI INDIA FULFORD INDIA/
SANOFI INDIA
 
P/E (TTM) x 398.8 34.3 1,161.1% View Chart
P/BV x 6.2 6.0 103.3% View Chart
Dividend Yield % 0.1 1.4 5.8%  

Financials

 FULFORD INDIA   SANOFI INDIA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
SANOFI INDIA
Dec-18
FULFORD INDIA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs9426,840 13.8%   
Low Rs4504,630 9.7%   
Sales per share (Unadj.) Rs691.41,203.1 57.5%  
Earnings per share (Unadj.) Rs11.5165.3 6.9%  
Cash flow per share (Unadj.) Rs15.4209.9 7.3%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.31.5 19.6%  
Book value per share (Unadj.) Rs380.0963.6 39.4%  
Shares outstanding (eoy) m3.9023.03 16.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.8 21.1%   
Avg P/E ratio x60.734.7 175.0%  
P/CF ratio (eoy) x45.327.3 165.8%  
Price / Book Value ratio x1.86.0 30.8%  
Dividend payout %17.450.8 34.3%   
Avg Mkt Cap Rs m2,714132,078 2.1%   
No. of employees `0000.43.3 13.5%   
Total wages/salary Rs m5054,068 12.4%   
Avg. sales/employee Rs Th6,073.08,393.8 72.4%   
Avg. wages/employee Rs Th1,137.41,232.4 92.3%   
Avg. net profit/employee Rs Th100.71,153.0 8.7%   
INCOME DATA
Net Sales Rs m2,69627,708 9.7%  
Other income Rs m125897 14.0%   
Total revenues Rs m2,82228,605 9.9%   
Gross profit Rs m-466,235 -0.7%  
Depreciation Rs m151,027 1.5%   
Interest Rs m107 135.7%   
Profit before tax Rs m546,098 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m102,292 0.4%   
Profit after tax Rs m453,806 1.2%  
Gross profit margin %-1.722.5 -7.6%  
Effective tax rate %17.737.6 47.0%   
Net profit margin %1.713.7 12.1%  
BALANCE SHEET DATA
Current assets Rs m1,73815,922 10.9%   
Current liabilities Rs m5456,235 8.7%   
Net working cap to sales %44.335.0 126.6%  
Current ratio x3.22.6 125.0%  
Inventory Days Days4864 76.1%  
Debtors Days Days421 20.6%  
Net fixed assets Rs m127,539 0.2%   
Share capital Rs m39230 17.0%   
"Free" reserves Rs m1,44321,962 6.6%   
Net worth Rs m1,48222,192 6.7%   
Long term debt Rs m00-   
Total assets Rs m2,07729,839 7.0%  
Interest coverage x6.7872.1 0.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.9 139.8%   
Return on assets %2.612.8 20.4%  
Return on equity %3.017.2 17.6%  
Return on capital %4.327.5 15.6%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m177,587 0.2%   
Fx outflow Rs m6737,145 9.4%   
Net fx Rs m-656442 -148.4%   
CASH FLOW
From Operations Rs m903,739 2.4%  
From Investments Rs m105-731 -14.3%  
From Financial Activity Rs m-14-1,972 0.7%  
Net Cashflow Rs m1811,036 17.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 3.8 14.4 26.4%  
FIIs % 0.1 14.6 0.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.5 201.9%  
Shareholders   4,783 15,184 31.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare FULFORD INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - AUROBINDO PHARMA COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS